Supercharged immune cells take on nasopharyngeal cancer
NCT ID NCT02065362
First seen Jan 31, 2026 · Last updated May 02, 2026 · Updated 10 times
Summary
This early-phase study tests a new immune cell therapy for people with a type of throat cancer linked to the Epstein-Barr virus. The treatment uses the patient's own T cells, which are modified in the lab to better recognize and attack the cancer while resisting a protein that tumors use to hide. The main goal is to check safety, with 14 participants receiving the cells after mild chemotherapy to help them work longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-POSITIVE NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.